Cargando…

Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics

Major bleeding risks associated with non-vitamin K oral anticoagulants (NOACs) used with and without concurrent antipsychotics in patients with non-valvular atrial fibrillation (AF) were assessed. A total of 98,863 patients with non-valvular AF receiving at least one NOAC prescription from Taiwan’s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chiung-Mei, Chang, Kuo-Hsuan, Wang, Chun-Li, Tu, Hui-Tzu, Huang, Yu-Tung, Wu, Hsiu-Chuan, Chang, Chien-Hung, Chang, Shang-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046567/ https://www.ncbi.nlm.nih.gov/pubmed/35496319 http://dx.doi.org/10.3389/fphar.2022.819878

Ejemplares similares

Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants
por: Wu, Victor Chien-Chia, et al.
Publicado: (2023)

The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
por: Lee, Kuang-Tso, et al.
Publicado: (2018)

Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—A nationwide cohort study
por: Wu, Hsin-Hsu, et al.
Publicado: (2022)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Safety and Effectiveness of Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study
por: Wang, Chun‐Li, et al.
Publicado: (2019)

Novel oral anticoagulant vs. warfarin in elderly atrial fibrillation patients with normal, mid‐range, and reduced left ventricular ejection fraction
por: Wu, Victor Chien‐Chia, et al.
Publicado: (2020)

Efficacy and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study
por: Wang, Chun‐Li, et al.
Publicado: (2018)

Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Resuming anticoagulation in patients with atrial fibrillation experiencing intracranial hemorrhage
por: Wu, Victor Chien-Chia, et al.
Publicado: (2021)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

Risk of Bleeding and Stroke with Oral Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation in Taiwan: A Nationwide Cohort Study
por: Chen, Pei-Chun, et al.
Publicado: (2015)

Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation
por: Xu, Yunwen, et al.
Publicado: (2022)

Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

The impact on renal function after long-term use of anticoagulants in atrial fibrillation patients
por: Lee, Wei-Chieh, et al.
Publicado: (2021)

Correction to: The impact on renal function after longterm use of anticoagulants in atrial fibrillation patients
por: Lee, Wei-Chieh, et al.
Publicado: (2021)

Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding
por: Scridon, Alina, et al.
Publicado: (2023)

Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation
por: Wintgens, L. I. S., et al.
Publicado: (2019)

Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation
por: Kinjo, Norito, et al.
Publicado: (2023)

Evaluation of the timing of using direct oral anticoagulants after ischemic stroke for patients with atrial fibrillation
por: Yu, Hui-Tzu, et al.
Publicado: (2023)

Editorial to “The differences of atrial thrombus locations and variable response to anticoagulation in non‐valvular atrial fibrillation with ventricular cardiomyopathy”
por: Chung, Wei‐Hsin, et al.
Publicado: (2020)

Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation
por: Silva Cunha, Pedro, et al.
Publicado: (2022)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation
por: Raposeiras Roubín, Sergio, et al.
Publicado: (2020)

Clinical Characteristics and Prognostic Factors of Non-Infectious Cerebral Venous Sinus Thrombosis
por: Chen, Yu-Chieh, et al.
Publicado: (2022)

Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients – A cohort study
por: Lee, Wei-Chieh, et al.
Publicado: (2022)

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction
por: Kuo, Jen-Yuan, et al.
Publicado: (2022)

Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage
por: Tsai, Chuan-Tsai, et al.
Publicado: (2020)

Surgical volume and outcomes of surgical ablation for atrial fibrillation: a nationwide population-based cohort study
por: Chang, Feng-Cheng, et al.
Publicado: (2023)

Atrial fibrillation and its arrhythmogenesis associated with insulin resistance
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

Oral Anticoagulant Therapy and Bleeding Events with Vitamin K Antagonists in Patients with Atrial Fibrillation in a Hungarian County Hospital
por: Mark, Laszlo, et al.
Publicado: (2015)

Performance of the ABC-bleeding risk score for assessing major bleeding risk in Chinese patients with atrial fibrillation on oral anticoagulation therapy: A real-world study
por: Wang, Yu-Feng, et al.
Publicado: (2022)

Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation
por: Kuo, Liang-Tseng, et al.
Publicado: (2021)

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v94136lt6o105206m88sfqtrjl